Suppr超能文献

志贺氏菌人体挑战模型。

The Shigella human challenge model.

机构信息

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, MS, USA.

Department of Live Attenuated Shigella Vaccines, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

出版信息

Epidemiol Infect. 2013 Feb;141(2):223-32. doi: 10.1017/S0950268812001677. Epub 2012 Aug 21.

Abstract

Shigella is an important bacterial cause of infectious diarrhoea globally. The Shigella human challenge model has been used since 1946 for a variety of objectives including understanding disease pathogenesis, human immune responses and allowing for an early assessment of vaccine efficacy. A systematic review of the literature regarding experimental shigellosis in human subjects was conducted. Summative estimates were calculated by strain and dose. While a total of 19 studies evaluating nine strains at doses ranging from 10 to 1 × 1010 colony-forming units were identified, most studies utilized the S. sonnei strain 53G and the S. flexneri strain 2457T. Inoculum solution and pre-inoculation buffering has varied over time although diarrhoea attack rates do not appear to increase above 75-80%, and dysentery rates remain fairly constant, highlighting the need for additional dose-ranging studies. Expansion of the model to include additional strains from different serotypes will elucidate serotype and strain-specific outcome variability.

摘要

志贺氏菌是全球范围内引起感染性腹泻的重要细菌病原体。自 1946 年以来,志贺氏菌人体挑战模型已被用于各种目的,包括了解疾病发病机制、人体免疫反应,并允许早期评估疫苗的功效。对人体志贺氏菌感染的实验研究进行了文献的系统综述。通过菌株和剂量计算了总结性估计。虽然总共确定了 19 项研究,评估了 9 个菌株在 10 到 1×1010 个菌落形成单位的剂量范围内,但大多数研究都使用了 S. sonnei 菌株 53G 和 S. flexneri 菌株 2457T。尽管腹泻攻击率似乎不会超过 75-80%,痢疾率保持相当稳定,但菌液和接种前缓冲液的变化随时间而变化,这突出表明需要进行更多的剂量范围研究。将模型扩展到包括来自不同血清型的其他菌株,将阐明血清型和菌株特异性结果的可变性。

相似文献

1
The Shigella human challenge model.
Epidemiol Infect. 2013 Feb;141(2):223-32. doi: 10.1017/S0950268812001677. Epub 2012 Aug 21.
2
The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal challenge after prior exposure.
Front Immunol. 2025 Jun 5;16:1586537. doi: 10.3389/fimmu.2025.1586537. eCollection 2025.
4
Epidemiology of Shigella species and serotypes in children: a retrospective substudy of the MAL-ED observational birth cohort study.
Lancet Microbe. 2025 Jun;6(6):101064. doi: 10.1016/j.lanmic.2024.101064. Epub 2025 Mar 26.
5
Shigellosis in Southeast Asia: A systematic review and meta-analysis.
Travel Med Infect Dis. 2023 Mar-Apr;52:102554. doi: 10.1016/j.tmaid.2023.102554. Epub 2023 Feb 16.
6
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13.
7
Causative species and serotypes of shigellosis in mainland China: systematic review and meta-analysis.
PLoS One. 2012;7(12):e52515. doi: 10.1371/journal.pone.0052515. Epub 2012 Dec 20.
8
9
10
Inactivated and subunit vaccines to prevent shigellosis.
Expert Rev Vaccines. 2009 Dec;8(12):1693-704. doi: 10.1586/erv.09.127.

引用本文的文献

1
The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal challenge after prior exposure.
Front Immunol. 2025 Jun 5;16:1586537. doi: 10.3389/fimmu.2025.1586537. eCollection 2025.
2
Dynamics of the gut microbiome in subjects challenged with 53G in a controlled human infection model.
mSphere. 2025 Apr 29;10(4):e0090624. doi: 10.1128/msphere.00906-24. Epub 2025 Mar 28.
3
Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.
Nat Rev Microbiol. 2025 May;23(5):303-317. doi: 10.1038/s41579-024-01126-x. Epub 2024 Nov 27.
4
Transforming vaccinology.
Cell. 2024 Sep 19;187(19):5171-5194. doi: 10.1016/j.cell.2024.07.021.
5
Statistical design and analysis of controlled human malaria infection trials.
Malar J. 2024 May 3;23(1):133. doi: 10.1186/s12936-024-04959-2.
6
Gastrointestinal signals in supplemented media reveal a role in adherence for the autotransporter gene.
Gut Microbes. 2024 Jan-Dec;16(1):2331985. doi: 10.1080/19490976.2024.2331985. Epub 2024 Mar 28.
7
Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019.
PLoS Negl Trop Dis. 2024 Feb 20;18(2):e0011964. doi: 10.1371/journal.pntd.0011964. eCollection 2024 Feb.
9
The increasing antimicrobial resistance of species among Iranian pediatrics: a systematic review and meta-analysis.
Pathog Glob Health. 2023 Oct;117(7):611-622. doi: 10.1080/20477724.2023.2179451. Epub 2023 Feb 16.
10
Quantitative dose-response analysis untangles host bottlenecks to enteric infection.
Nat Commun. 2023 Jan 28;14(1):456. doi: 10.1038/s41467-023-36162-3.

本文引用的文献

1
Post-infectious irritable bowel syndrome--a review of the literature.
Z Gastroenterol. 2011 Aug;49(8):997-1003. doi: 10.1055/s-0031-1281581. Epub 2011 Aug 2.
2
Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention.
J Am Med Assoc. 1946 Oct 19;132:362-8. doi: 10.1001/jama.1946.02870420002002.
3
Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome.
Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44. doi: 10.1111/j.1365-2036.2007.03399.x.
4
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
Nat Rev Microbiol. 2007 Jul;5(7):540-53. doi: 10.1038/nrmicro1662.
5
Infection and musculoskeletal conditions: Reactive arthritis.
Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1119-37. doi: 10.1016/j.berh.2006.08.008.
6
Postinfectious irritable bowel syndrome--a meta-analysis.
Am J Gastroenterol. 2006 Aug;101(8):1894-9; quiz 1942. doi: 10.1111/j.1572-0241.2006.00654.x.
8
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.
Clin Infect Dis. 2006 May 1;42(9):1283-8. doi: 10.1086/503039. Epub 2006 Mar 22.
9
Challenge studies of human volunteers: ethical issues.
J Med Ethics. 2004 Feb;30(1):110-6. doi: 10.1136/jme.2003.004440.
10
The ethical challenge of infection-inducing challenge experiments.
Clin Infect Dis. 2001 Oct 1;33(7):1028-33. doi: 10.1086/322664. Epub 2001 Sep 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验